Relay Therapeutics Stock Buy Hold or Sell Recommendation
| RLAY Stock | USD 4.75 0.11 2.37% |
Given the investment horizon of 90 days and your slightly conservative level of risk, our recommendation regarding Relay Therapeutics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Relay Therapeutics given historical horizon and risk tolerance towards Relay Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Relay Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Relay Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide. In addition, we conduct extensive research on individual companies such as Relay and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Relay Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Relay |
Execute Relay Therapeutics Buy or Sell Advice
The Relay recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Relay Therapeutics. Macroaxis does not own or have any residual interests in Relay Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Relay Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Relay Therapeutics Trading Alerts and Improvement Suggestions
| Relay Therapeutics generated a negative expected return over the last 90 days | |
| Relay Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 25.55 M. Net Loss for the year was (341.97 M) with profit before overhead, payroll, taxes, and interest of 1.38 M. | |
| Relay Therapeutics currently holds about 1.05 B in cash with (300.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Down -27.93 percent in 4 Weeks, Heres Why Relay Therapeutics Looks Ripe for a Turnaround |
Relay Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Relay analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Relay analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Relay Therapeutics Returns Distribution Density
The distribution of Relay Therapeutics' historical returns is an attempt to chart the uncertainty of Relay Therapeutics' future price movements. The chart of the probability distribution of Relay Therapeutics daily returns describes the distribution of returns around its average expected value. We use Relay Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Relay Therapeutics returns is essential to provide solid investment advice for Relay Therapeutics.
| Mean Return | -0.48 | Value At Risk | -6.47 | Potential Upside | 4.82 | Standard Deviation | 7.48 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Relay Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Relay Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Relay Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Relay Therapeutics back and forth among themselves.
| Shares | Logos Global Management Lp | 2024-06-30 | 2.6 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.5 M | Geode Capital Management, Llc | 2024-06-30 | 2.4 M | Mpm Oncology Impact Management Lp | 2024-09-30 | 2 M | Boxer Capital Llc | 2024-09-30 | 1.8 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.7 M | Finepoint Capital Lp | 2024-06-30 | 1.6 M | Alphabet Inc | 2024-06-30 | 1.6 M | Goldman Sachs Group Inc | 2024-06-30 | 1.5 M | Sb Investment Advisers (uk) Ltd | 2024-09-30 | 27.9 M | Vanguard Group Inc | 2024-09-30 | 14.5 M |
Relay Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (319.0M) | 81.7M | (450.7M) | (188.7M) | 51.0M | 53.6M | |
| Change In Cash | (379.6M) | 405.7M | (165.8M) | (128.3M) | (7.9M) | (7.5M) | |
| Free Cash Flow | (74.1M) | (104.4M) | (77.9M) | (238.6M) | (304.4M) | (289.2M) | |
| Depreciation | 2.8M | 3.5M | 3.9M | 4.1M | 5.3M | 4.0M | |
| Other Non Cash Items | (2.4M) | (416K) | 137.7M | (10.5M) | (17.2M) | (16.3M) | |
| Capital Expenditures | 8.0M | 1.9M | 3.5M | 9.1M | 4.1M | 5.2M | |
| Net Income | (75.3M) | (52.4M) | (363.9M) | (290.5M) | (342.0M) | (324.9M) | |
| End Period Cash Flow | 42.8M | 448.5M | 282.7M | 154.4M | 146.4M | 199.6M | |
| Change To Netincome | 2.0M | 31.5M | 51.3M | 56.1M | 64.6M | 67.8M |
Relay Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Relay Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Relay Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Relay stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.89 | |
β | Beta against Dow Jones | 3.98 | |
σ | Overall volatility | 7.55 | |
Ir | Information ratio | -0.08 |
Relay Therapeutics Volatility Alert
Relay Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Relay Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Relay Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Relay Therapeutics Fundamentals Vs Peers
Comparing Relay Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Relay Therapeutics' direct or indirect competition across all of the common fundamentals between Relay Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Relay Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Relay Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Relay Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Relay Therapeutics to competition |
| Fundamentals | Relay Therapeutics | Peer Average |
| Return On Equity | -0.43 | -0.31 |
| Return On Asset | -0.27 | -0.14 |
| Operating Margin | (39.47) % | (5.51) % |
| Current Valuation | (13.14 M) | 16.62 B |
| Shares Outstanding | 167.38 M | 571.82 M |
| Shares Owned By Insiders | 1.71 % | 10.09 % |
| Shares Owned By Institutions | 98.17 % | 39.21 % |
| Number Of Shares Shorted | 12.04 M | 4.71 M |
| Price To Book | 0.93 X | 9.51 X |
| Price To Sales | 77.62 X | 11.42 X |
| Revenue | 25.55 M | 9.43 B |
| Gross Profit | 1.38 M | 27.38 B |
| EBITDA | (374.15 M) | 3.9 B |
| Net Income | (341.97 M) | 570.98 M |
| Cash And Equivalents | 1.05 B | 2.7 B |
| Cash Per Share | 8.72 X | 5.01 X |
| Total Debt | 53.47 M | 5.32 B |
| Debt To Equity | 0.06 % | 48.70 % |
| Current Ratio | 15.22 X | 2.16 X |
| Book Value Per Share | 5.03 X | 1.93 K |
| Cash Flow From Operations | (300.32 M) | 971.22 M |
| Short Ratio | 8.26 X | 4.00 X |
| Earnings Per Share | (2.61) X | 3.12 X |
| Price To Earnings To Growth | 0.07 X | 4.89 X |
| Target Price | 21.91 | |
| Number Of Employees | 294 | 18.84 K |
| Beta | 1.68 | -0.15 |
| Market Capitalization | 776.66 M | 19.03 B |
| Total Asset | 843.98 M | 29.47 B |
| Retained Earnings | (1.4 B) | 9.33 B |
| Working Capital | 739.83 M | 1.48 B |
| Net Asset | 843.98 M |
Note: Disposition of 2300 shares by Thomas Catinazzo of Relay Therapeutics at 5.95 subject to Rule 16b-3 [view details]
Relay Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Relay . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 176058.0 | |||
| Daily Balance Of Power | 0.3929 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 4.76 | |||
| Day Typical Price | 4.76 | |||
| Price Action Indicator | 0.045 | |||
| Period Momentum Indicator | 0.11 |
About Relay Therapeutics Buy or Sell Advice
When is the right time to buy or sell Relay Therapeutics? Buying financial instruments such as Relay Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Relay Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Books Thematic Idea Now
Books
Companies involved in publishing of books, newspapers, periodicals and other mass publications. The Books theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Books Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.